News & Updates
Tempus will now offer the ArteraAI Prostate Test to cancer centers across the U.S. Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, and Tempus, a technology company leading the adoption of AI to advance precision medicine and patient care, announced today that they…
Read More
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are expected in 2025 Excerpt from the Press Release: CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd.…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), today announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome (MPS II) in the 24-week treatment period and additional long-term follow-up of its investigational therapeutic tividenofusp alfa (DNL310). These…
Read More
By identifying biomarkers of brain disorders, Cove Neurosciences is working to speed up the development of new treatments. Excerpt from the Press Release: “We know that every patient is different. No two patients with dementia are the same,” says Toronto neurology resident and entrepreneur Nardin Samuel. And yet, she adds, they may end up with…
Read More
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, today announced the first patient has been dosed in…
Read More
Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development Excerpt from the Press Release: SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — Replicate Bioscience, a clinical-stage company pioneering novel self-replicating…
Read More
Excerpt from the Press Release: Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated dual PARP/Wnt pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific patient selection technology—the Drug Response Predictor (DRP®)—today announced plans for the next step in advancing…
Read More
Excerpt from the Press Release: BOSTON, Feb. 6, 2025 /PRNewswire/ — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that Cohort 3 of its Phase 1 clinical trial enrolled three patients and all have been dosed with TTX-MC138, its lead candidate. The Safety…
Read More
Topline data from an interim analysis of the fourth cohort of its Phase 1b Multiple-Ascending Dose (MAD) clinical trial showed continued mechanistic dose response Exploratory results of imaging-based biomarkers continued to show reduction in height-adjusted total kidney volume (htTKV) growth rate Successful End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA) with agreement…
Read More
First Patient enrolled and treated at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon Advances Hemopurifier® Study in Solid Tumors Not Responding to Anti-PD-1 Antibodies Excerpt from the Press Release: SAN DIEGO, Jan. 29, 2025 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer…
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?